Introduction
cancer, Colorectal cancer, rectosigmoid cancer
CANCER, COLORECTAL CANCER, SILS
Colorectal cancer is the third most common cancer in China with an estimated 550,000 newly diagnosed cases each year [We performed an RCT of CLS versus SILS + 1 in patients with rectosigmoid cancer and previously reported the short-term results. Thus, the aim of this study is to assess the long-term oncological efficacy after SILS + 1 or CLS for rectosigmoid cancer.